Molecular mechanisms of plasmid maintenance in multiply-resistant staphylococci [ 2007 - 2009 ]

Research Grant

Researchers: A/Pr Neville Firth (Principal investigator) ,  A/Pr Maria Schumacher ,  A/Pr Slade Jensen ,  Dr Stephen Kwong ,  Prof Ronald Skurray

Brief description Serious infections caused by Staphylococcus aureus bacteria, commonly known as Golden Staph, often arise as complications in patients within hospitals. These infections compromise the health of the patient and jeopardise their recovery from the condition for which they were initially admitted, which significantly increases healthcare costs. Golden Staph is a major cause of hospital-acquired infections in Australia and globally. The problem is largely due to the presence in hospitals of strains that are resistant to most clinically-useful antibiotics and are therefore very difficult to eradicate; the recent isolation of strains highly-resistant to one of the last resort anti-staphylococcal antibiotics, vancomycin, is particularly worrying, as is the emergence of resistant strains that cause infections in the wider community. The emergence of these multiresistant strains is primarily attributable to the acquisition of pre-existing resistance determinants by cell-to-cell gene transfer, a process in which plasmids, extra-chromosomal DNA elements, play a prominent role. Staphylococcal multiresistance plasmids carry genes that can confer resistance to up to 20 antimicrobial agents and are themselves capable of transfer between bacterial cells. In this project, we will define the molecular mechanisms by which multiresistance plasmids efficiently replicate in the host cell and are stably maintained in bacterial populations. This information will identify targets for agents that can promote the loss of plasmids and hence combat the development of resistance; the activity of one type of agent will be determined in this project. The application of knowledge arising from these studies to has the potential to extend the efficacy of existing and future antimicrobial therapies.

Funding Amount $AUD 543,778.39

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant